AIM: To investigate variants of immunity-related GTPase family M (IRGM) and NKX2-3 genes and genotype-phenotype in Eastern European patients with inflammatory bowel disease (IBD). METHODS: We analyzed 1707 Hungarian and Czech subjects with Crohn's disease (CD) (n = 810, age: 37.1 ± 12.6 years, duration: 10.7 ± 8.4 years) and ulcerative colitis (UC) (n = 428, age: 43.7 ± 15.0 years, duration: 12.6 ± 9.9 years), as well as 469 healthy controls. IRGM rs13361189, NKX2-3 rs10883365 and ECM1 rs13294 polymorphisms were tested by LightCycler allele discrimination. Detailed clinical phenotypes were determined by reviewing the medical charts. RESULTS: NKX2-3 rs10883365 variant allele was associated with increased risk for CD (P = 0.009, OR = 1.24, 95% CI = 1.06-1.48) and UC (P = 0.001, OR = 1.36, 95% CI = 1.13-1.63), whereas variant IRGM allele increased risk for CD (P = 0.029, OR = 1.36, 95% CI = 1.03-1.79). In contrast, ECM1 rs13294 was not associated with either CD or UC. In CD, the variant IRGM allele was associated with a colon-only location (P = 0.02, OR = 1.62, 95% CI = 1.07-2.44), whereas in UC, the ECM1 variant was associated with cutaneous manifestations (P = 0.002, OR = 3.36, 95% CI = 1.48-7.63). Variant alleles did not predict resistance to steroids or azathioprine, efficacy of infliximab, or need for surgery. CONCLUSION: NKX2-3 and IRGM are susceptibility loci for IBD in Eastern European patients. Further studies are needed to confirm the reported phenotype-genotype associations.
AIM: To investigate variants of immunity-related GTPase family M (IRGM) and NKX2-3 genes and genotype-phenotype in Eastern European patients with inflammatory bowel disease (IBD). METHODS: We analyzed 1707 Hungarian and Czech subjects with Crohn's disease (CD) (n = 810, age: 37.1 ± 12.6 years, duration: 10.7 ± 8.4 years) and ulcerative colitis (UC) (n = 428, age: 43.7 ± 15.0 years, duration: 12.6 ± 9.9 years), as well as 469 healthy controls. IRGMrs13361189, NKX2-3rs10883365 and ECM1rs13294 polymorphisms were tested by LightCycler allele discrimination. Detailed clinical phenotypes were determined by reviewing the medical charts. RESULTS:NKX2-3rs10883365 variant allele was associated with increased risk for CD (P = 0.009, OR = 1.24, 95% CI = 1.06-1.48) and UC (P = 0.001, OR = 1.36, 95% CI = 1.13-1.63), whereas variant IRGM allele increased risk for CD (P = 0.029, OR = 1.36, 95% CI = 1.03-1.79). In contrast, ECM1rs13294 was not associated with either CD or UC. In CD, the variant IRGM allele was associated with a colon-only location (P = 0.02, OR = 1.62, 95% CI = 1.07-2.44), whereas in UC, the ECM1 variant was associated with cutaneous manifestations (P = 0.002, OR = 3.36, 95% CI = 1.48-7.63). Variant alleles did not predict resistance to steroids or azathioprine, efficacy of infliximab, or need for surgery. CONCLUSION:NKX2-3 and IRGM are susceptibility loci for IBD in Eastern European patients. Further studies are needed to confirm the reported phenotype-genotype associations.
Authors: Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren Journal: Can J Gastroenterol Date: 2005-09 Impact factor: 3.522
Authors: Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho Journal: Science Date: 2006-10-26 Impact factor: 47.728
Authors: Andre Franke; Tobias Balschun; Tom H Karlsen; Jürgen Hedderich; Sandra May; Tim Lu; Dörthe Schuldt; Susanna Nikolaus; Philip Rosenstiel; Michael Krawczak; Stefan Schreiber Journal: Nat Genet Date: 2008-04-27 Impact factor: 38.330
Authors: Jochen Hampe; Andre Franke; Philip Rosenstiel; Andreas Till; Markus Teuber; Klaus Huse; Mario Albrecht; Gabriele Mayr; Francisco M De La Vega; Jason Briggs; Simone Günther; Natalie J Prescott; Clive M Onnie; Robert Häsler; Bence Sipos; Ulrich R Fölsch; Thomas Lengauer; Matthias Platzer; Christopher G Mathew; Michael Krawczak; Stefan Schreiber Journal: Nat Genet Date: 2006-12-31 Impact factor: 38.330
Authors: Miles Parkes; Jeffrey C Barrett; Natalie J Prescott; Mark Tremelling; Carl A Anderson; Sheila A Fisher; Roland G Roberts; Elaine R Nimmo; Fraser R Cummings; Dianne Soars; Hazel Drummond; Charlie W Lees; Saud A Khawaja; Richard Bagnall; Denis A Burke; Catherine E Todhunter; Tariq Ahmad; Clive M Onnie; Wendy McArdle; David Strachan; Graeme Bethel; Claire Bryan; Cathryn M Lewis; Panos Deloukas; Alastair Forbes; Jeremy Sanderson; Derek P Jewell; Jack Satsangi; John C Mansfield; Lon Cardon; Christopher G Mathew Journal: Nat Genet Date: 2007-06-06 Impact factor: 38.330
Authors: A N Ananthakrishnan; E C Oxford; D D Nguyen; J Sauk; V Yajnik; R J Xavier Journal: Aliment Pharmacol Ther Date: 2013-07-14 Impact factor: 8.171
Authors: Scott Plevy; Mark S Silverberg; Steve Lockton; Tom Stockfisch; Lisa Croner; Jordan Stachelski; Michelle Brown; Cheryl Triggs; Emil Chuang; Fred Princen; Sharat Singh Journal: Inflamm Bowel Dis Date: 2013-05 Impact factor: 5.325
Authors: Maria Gazouli; Nikolas Dovrolis; Andre Franke; George M Spyrou; Leonardo A Sechi; George Kolios Journal: Gut Pathog Date: 2019-06-15 Impact factor: 4.181